Drug Trial Radar · NCT06194552
A Multiple Dose Study of the Safety and Pharmacokinetics of NTRX-07
Last checked: Nov 19, 2026Latest source record: Jan 8, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
32
Actual
Start
Sep 6, 2022
Primary completion
May 31, 2023
Study completion Jun 30, 2023
Sponsor
- Lead sponsor
- NeuroTherapia, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- CRU Early Phase Unit Kistarcsa
- First posted
- Jan 8, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 45 years, up to 80 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a Phase 1, Randomized, Placebo-Controlled, Modified Parallel Design Multiple Ascending Dose Study of NTRX 07 to Assess Safety and Tolerability and Pharmacokinetics in Adult Healthy Volunteers and Subjects with MCI or Early AD. In addition, an exploratory study of the effect of a high fat meal was conducted.
Conditions
- Alzheimer Disease
Interventions
NTRX-07Drug
Investigational orally administered CB2 agonist
PlaceboDrug
Matched placebo administered orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment-Related Adverse EventsTime frame: From admission to discharge, up to 2 weeks
Locations
2 sites in 2 countries. Site status is shown where the registry gives one.
NeuroTherapia
Gates Mills, Ohio
CRU Early Phase Unit Kistarcsa
Kistarcsa, Hungary
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.